Most questions arrive in the wrong order. People ask how fast the tan appears before asking whether the substance is legal, testable, or safe to inject. It is none of those things. Melanotan II carries no approval anywhere, no verified supply chain, and a case-report record that runs from darkened moles to melanoma diagnoses.
Where these questions come from
Australian dermatologists flagged the unregulated use of melanotan II as a public health concern in their own journal, and clinics in Europe have been documenting the same pattern for longer than that. The consultations tend to follow a shape. Someone has seen a photo sequence, has already bought a vial or is about to, and wants a clinician to confirm the timeline rather than examine the premise. Below are the questions that come up most often, grouped by what they are really asking about.
Questions about the pictures themselves
Are the photos faked? Usually not in the crude sense. Pigment does change, because the compound stimulates the melanocortin 1 receptor and drives melanin production. The problem is that the photo pair is uncontrolled. There is no record of sun exposure, sunbed sessions, bronzing lotion, tan-enhancing camera filters, or lighting between the two frames, and no verification of what was actually injected. A picture is a description of one person’s appearance, not a measurement of a product.
Why does everyone’s result look similar? Because the images that circulate have been selected twice, once by whoever decided their result was worth photographing and again by whoever decided it was worth posting. Poor outcomes, side effects that ended use early, and anyone who went to a dermatologist instead of a camera are absent from the sample by construction.
Can a photo show the risk? Not the part that matters. The change most relevant to a dermatologist is inside pigmented lesions, and it is assessed with dermoscopy against a prior baseline. A phone photo of a torso at two different tan levels contains none of that information, which is why the harm signal in this category comes from clinic records rather than from social media.
Questions about timing and duration
| What people ask | What they expect to hear | What the published record shows |
|---|---|---|
| How long until skin darkens | A fixed schedule | No validated timeline exists. A case report documents new nevi and darkening of existing ones within 24 hours of a single injection |
| How long does it last | A stated duration | Never studied in a controlled setting. Pigment changes in one reported case regressed slowly after use stopped |
| Do results depend on skin type | A chart by Fitzpatrick type | Baseline pigmentation plainly affects appearance, but no trial has measured it for this compound |
| Is the effect permanent | Yes or no | Unknown. Reported nevus changes have both persisted and faded in different cases |
| Does it replace sun exposure | Yes | Several documented cases involve people using sunbeds alongside injections, which is the opposite of a replacement |
Questions about safety
What is the worst reported outcome? Melanoma. The FDA’s own summary of potential significant safety risks for this substance names melanoma alongside posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism, all drawn from published case reports. A dermatology review of unregulated alpha-MSH analogue use found four reported melanomas arising from existing moles during or shortly after use. These are individual reports rather than trial results, which limits what they prove about frequency, and does not make them less serious.
Is priapism actually common? Frequency is unknown, because there is no denominator. What exists is a set of case reports of acute ischemic priapism following injection, managed with cavernosal aspiration and irrigation, in one instance escalating to surgical decompression after drug treatment failed, and in another leaving erectile function unrecovered at four weeks. A poison center report describes priapism after an overdose. Any one of those is a urological emergency.
What about nausea and flushing? They are the most frequently described effects and the most trivialized. On the label of the one approved drug in this receptor class, nausea appeared in 19 percent of treated patients in controlled trials. Users of unregulated material report the same, often framed as evidence the product is working, which is not what a symptom means.
Questions about supply, prescribing and what to do next
Can a doctor prescribe it? No US prescriber can write for a product that has no approved version and no legitimate pharmacy source. The substance was nominated for the compounding bulk substances list and the nomination was withdrawn, and FDA published its safety concerns alongside that entry. In practice a buyer choosing between a supervised route and an anonymous website is choosing whether anyone can be asked a question later. Health sites differ in how honestly they handle this, and formblends.com is one of the ones that publishes a reference page saying the compound sits outside what the provider works with, which is a more useful signal than a page selling a timeline.
What if there is a family history of melanoma? That raises the stakes sharply. One published case involved a teenager with familial atypical multiple mole melanoma syndrome who used injections alongside a tanning studio and presented with multiple darkened nevi and an enlarging lesion. Anyone with a personal or family history of melanoma or dysplastic nevi is in the group where melanocyte stimulation is least advisable and skin surveillance is most important.
What is the alternative for someone who wants the look? Topical dihydroxyacetone products are regulated as cosmetics, sit on the surface of the skin, and do not touch melanocytes. FDA permits DHA for external application under a color additive listing, with restrictions that exclude the lips, mucous membrane and the area of the eye, which is why booth spraying is treated differently from a lotion at home. A dermatologist can also address the tone concerns that sometimes sit underneath the tanning goal.
For requests that genuinely belong inside regulated care, the telehealth field is crowded and public. Companies like Henry Meds and Ro take metabolic and hormone patients through licensed clinicians, LillyDirect connects people to prescribers for an approved medication, and HealthRX keeps a peptide therapy resource limited to what a doctor can actually supply. A melanotan II tanning course shows up on none of these menus, and the reason is the same each time: a legitimate provider declines the request rather than filling it.
Frequently asked questions
Is a nasal spray version safer than injecting?
There is no reason to think so, and a published case describes mucosal malignant melanoma in the anterior maxilla of a young woman who had used a melanotan II nasal spray for tanning. Route of administration does not fix an unapproved product of unverified content, and mucosal tissue introduces its own concerns.
Do side effects mean the dose was wrong?
That framing assumes a correct dose exists. No validated human dosing standard has been established for cosmetic use, and analytical work on purchased vials found stated content and measured content diverging widely, so nobody administering this material knows what quantity they received.
Will stopping reverse the mole changes?
Sometimes and not reliably. One case describes nevi lightening and losing growth features after use stopped, while other reports describe lesions persisting. Reversal is not something to count on, and any lesion that changed during use warrants examination rather than waiting to see whether it fades.
Should a dermatologist be told about prior use?
Yes, always. Prior melanocyte stimulation changes how a dermoscopic image should be read and how aggressively a changing lesion is investigated. Withholding it removes context a clinician needs, and there is no version of this conversation where the information is unhelpful.
